palmidrol has been researched along with Basal Ganglia Diseases in 2 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 9.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 5.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "Patients in the acute phase of mania were assigned into two parallel groups given either lithium (blood level of 0." | 3.11 | Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. ( Abedini, T; Akhondzadeh, S; Ardakani, MK; Ghannadi, F; Hosseyni, R; Moghaddam, HS; Talaei, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abedini, T | 1 |
| Hosseyni, R | 1 |
| Ghannadi, F | 1 |
| Moghaddam, HS | 1 |
| Ardakani, MK | 1 |
| Talaei, A | 1 |
| Akhondzadeh, S | 2 |
| Salehi, A | 1 |
| Namaei, P | 1 |
| TaghaviZanjani, F | 1 |
| Bagheri, S | 1 |
| Moradi, K | 1 |
| Khodaei Ardakani, MR | 1 |
2 trials available for palmidrol and Basal Ganglia Diseases
| Article | Year |
|---|---|
Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial.
Topics: Amides; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Double-Bli | 2022 |
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
Topics: Amides; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, Combination | 2022 |